Children with antibody-associated vasculitis, for instance, have a higher likelihood of upper airway disease and potentially severe lower airway disease.
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response after a COVID-19 vaccine primary series, and whether a booster changes patient response.
email article
Treatment with intravenous immunoglobulins (IVIG) for dermatomyositis was effective in a pivotal phase III randomized trial, a researcher reported.
At week 16, 78.72% of patients receiving IVIG were considered responders versus 43.75% among those given placebo, which represented a difference of 34.97% (95% CI 16.70-53.24,
P=0.0008). This was a highly significant difference, said Rohit Aggarwal, MD, co-director of the Myositis Center at the University of Pittsburgh, during a plenary abstract session at the European League Against Rheumatism (EULAR) virtual congress. Dermatomyositis is a rare, chronic autoimmune disease characterized by progressive proximal muscle weakness and a characteristic skin rash, he explained. Current therapeutic options include corticosteroids, other immunosuppressants, and IVIG. However, none of these therapies have been evaluated in phase III studies.